October 8th 2025
The BeeLine trial is a placebo-controlled study designed to evaluate radiprodil’s impact on both seizure frequency and non-seizure symptoms associated with GRIN-NDD.
Developing biomarkers for gut and neurological, cognitive functioning associations in children
September 7th 2023In this Contemporary Pediatrics interview, Rob Knight, PhD, discusses translating adult studies into children to determine gut microbiome biomarkers, and how they are associated with neurological and cognitive conditions.
How are gut microbiomes and pediatric neurological, cognitive conditions being linked?
August 28th 2023Rob Knight, PhD, Wolfe Endowed Chair in Microbiome Science at Rady Children's Hospital-San Diego, professor of pediatrics, UCSD, explains how links between gut microbiomes and cognitive and neurological conditions are being researched and what could be ahead for these associations in children.
Potential links between neurological, cognitive conditions and gut microbiomes of children
August 17th 2023Watch as Rob Knight, PhD, Wolfe Endowed Chair in Microbiome Science at Rady Children's Hospital-San Diego, professor of pediatrics, UCSD, talks the gut microbiome and the potential associations with cognitive and neurological conditions in children, and why the topic is gaining interest and momentum.
Antidepressant use during pregnancy does not increase risk of neurodevelopmental disorders
October 7th 2022Although crude results of a study showed risk of neurodevelopmental disorders doubling when exposed to antidepressants during pregnancy, these results were not observed in a fully adjusted analysis.
Pilot study highlights outcome preferences for adolescents with chronic migraine, their parents
June 3rd 2022More than 60% of adolescents felt that it was more important to measure decreases in the frequency and intensity of headaches in terms of severe headaches/spikes rather than total headache days.
First patient treated in adolescent epilepsy trial assessing NeuroPace RNS system
May 17th 2022Since its approval for the treatment of medical refractory epilepsy in 2013, the closed-loop neuromodulation device has had its efficacy and safety confirmed in several pivotal studies and will now be assessed in focal epilepsy in the RESPONSE trial.